Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Public ClinicalTrials.gov record NCT04925284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.
Study identification
- NCT ID
- NCT04925284
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 269 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 7, 2021 (Actual)
- Primary completion
- Mar 10, 2025 (Actual)
- Completion
- Mar 10, 2025 (Actual)
- Last update posted
- Apr 4, 2025
2021 – 2025
United States locations
- U.S. sites
- 34
- U.S. states
- 19
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #48 | Birmingham | Alabama | 35294 | — |
| Exelixis Clinical Site #20 | Tucson | Arizona | 85704 | — |
| Exelixis Clinical Site#95 | Tucson | Arizona | 85719 | — |
| Exelixis Clinical Site#58 | Little Rock | Arkansas | 72205 | — |
| Exelixis Clinical Site#59 | Fountain Valley | California | 92708 | — |
| Exelixis Clinical Site #21 | Los Angeles | California | 90025 | — |
| Exelixis Clinical Site #26 | Los Angeles | California | 90404 | — |
| Exelixis Clinical Site #16 | New Haven | Connecticut | 06511 | — |
| Exelixis Clinical Site #22 | Washington D.C. | District of Columbia | 20007 | — |
| Exelixis Clinical Site#93 | Chicago | Illinois | 60637 | — |
| Exelixis Clinical Site #6 | Baltimore | Maryland | 21287 | — |
| Exelixis Clinical Site #18 | Columbia | Maryland | 21044 | — |
| Exelixis Clinical Site #25 | Boston | Massachusetts | 02215 | — |
| Exelixis Clinical Site #19 | Detroit | Michigan | 48202 | — |
| Exelixis Clinical Site #10 | Detroit | Michigan | 49201 | — |
| Exelixis Clinical Site #5 | St Louis | Missouri | 63110 | — |
| Exelixis Clinical Site #11 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #8 | East Brunswick | New Jersey | 08816 | — |
| Exelixis Clinical Site #7 | New Brunswick | New Jersey | 08903 | — |
| Exelixis Clinical Site #23 | Albany | New York | 12206 | — |
| Exelixis Clinical Site#67 | Lake Success | New York | 11042 | — |
| Exelixis Clinical Site #12 | New York | New York | 10016 | — |
| Exelixis Clinical Site #15 | Cleveland | Ohio | 44106 | — |
| Exelixis Clinical Site #29 | Cleveland | Ohio | 44195 | — |
| Exelixis Clinical Site #49 | Hilliard | Ohio | 43026 | — |
| Exelixis Clinical Site #4 | Oklahoma City | Oklahoma | 73104 | — |
| Exelixis Clinical Site #3 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #24 | Austin | Texas | 78705 | — |
| Exelixis Clinical Site #1 | Austin | Texas | 78758 | — |
| Exelixis Clinical Site #32 | Dallas | Texas | 75246 | — |
| Exelixis Clinical Site #14 | Dallas | Texas | 75390 | — |
| Exelixis Clinical Site#92 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #2 | San Antonio | Texas | 78229 | — |
| Exelixis Clinical Site #9 | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04925284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04925284 live on ClinicalTrials.gov.